AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3190970
Drug: Midazolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.4 mg kg‐1
Trial: 3190970
Drug: Midazolam 0.4-0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.4-0.5 mg kg‐1
Trial: 3190970
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (all doses)
Trial: 3190970
Drug: Midazolam (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (all doses)
Trial: 3190970
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of both premedicants
Trial: 31515843
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of 1.5 g of cefuroxime
Trial: 31515843
Drug: Short-term infusion
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term infusion (STI) of 1.5 g of cefuroxime
Trial: 26077459
Drug: Therapeutic regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic regimen of Traditional Chinese Medicine (TCM) rehabilitation
Trial: 23528400
Drug: Licopid as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licopid as immunocorrective agent
Trial: 23528400
Drug: Antifungal and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal and antimicrobial treatment, eubiotics and bacteriophages
Trial: 16685010
Drug: Terbutaline, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline, 0.5 mg
Trial: 3332610
Drug: Bromocriptine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine at doses up to 20 mg/day
Trial: 27287699
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg every 4 weeks plus placebo
Trial: 27287699
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg every 4 weeks plus ezetimibe
Trial: 27287699
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg every 4 weeks plus fenofibrate
Trial: 16022756
Drug: Fermented soya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented soya milk (40 mg isoflavone)
Trial: 16022756
Drug: Increasing isoflavone
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing isoflavone dosage
Trial: 16022756
Drug: Modest dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modest dosage (20-30 mg/d)
Trial: 14727988
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate 200 mg/day (capsules)
Trial: 14727988
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate 160 mg once daily (tablet)
Trial: 14727988
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate (tablet and capsule formulations)
Trial: 7781149
Drug: Oral trofosfamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trofosfamide, escalated doses every 3rd week until grade 2 leukopenia
Trial: 2281055
Drug: Amiloride inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride inhalation (0.3 mg/ml)
Trial: 24453924
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline inhalation
Trial: 31503309
Drug: Multicomponent home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent home-based physical therapy intervention (training)
Trial: 28911357
Drug: Combination intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination intervention package to improve early initiation of ART and anti-tuberculosis treatment success
Trial: 17940861
Drug: Integrated individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated individual cognitive-behavioral treatment and HIV prevention intervention
Trial: 16219571
Drug: Delayed intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed intensification followed by maintenance chemotherapy
Trial: 7547040
Drug: Spinal amethocaine
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal amethocaine 12 mg in 2 ml of 5% glucose
Trial: 7547040
Drug: Spinal amethocaine
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal amethocaine 14 mg in 2 ml of 5% glucose
Trial: 7547040
Drug: Spinal amethocaine
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal amethocaine 8 mg in 2 ml of 5% glucose
Trial: 1540304
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid (15 mg bid, po)
Trial: 3886712
Drug: Arildone in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arildone in vanishing cream
Trial: 3886712
Drug: Arildone in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arildone in DMSO solution
Trial: 3886712
Drug: Vanishing cream
RxNorm normalized name: Vanishing Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanishing cream vehicle without arildone
Trial: 3886712
Drug: DMSO solution
RxNorm normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DMSO solution vehicle without arildone
Trial: 30053897
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow nasal oxygen therapy (HFNO2)
Trial: 30053897
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy (standard low flow oxygen therapy)
Trial: 27026675
Drug: Trastuzumab (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (high dose: 8 mg/kg)
Trial: 27026675
Drug: Trastuzumab (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (low dose: 4 mg/kg)
Trial: 21116604
Drug: GAD‐alum (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD‐alum (20 μg subcutaneous injection at baseline and 1 month later)
Trial: 21116604
Drug: Placebo (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous injection at baseline and 1 month later)
Trial: 9695723
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine 21 mg/24 hr
Trial: 9695723
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine 42 mg/24 hr
Trial: 9695723
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine 63 mg/24 hr
Trial: 9695723
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (all doses)
Trial: 9695723
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine with smoking
Trial: 7626984
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (erythropoietin + calcitriol)
Trial: 7626984
Drug: Erythropoietin monotherapy
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin monotherapy
Trial: 31996953
Drug: Interferon beta/interleukin-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta/interleukin-2 immunotherapy added to first-line salvage hormone therapy (HT)
Trial: 31996953
Drug: Historical controls
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical controls receiving first-line salvage hormone therapy (HT)
Trial: 28964890
Drug: ABT‐981 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐981 (0.3, 1, or 3 mg/kg) every other week for a total of four SC injections
Trial: 28964890
Drug: ABT‐981 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐981 (3 mg/kg) every 4 weeks for a total of three SC injections
Trial: 22674612
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 on day 1, every 3 weeks)
Trial: 15064218
Drug: Physician-administered intervention
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician-administered intervention
Trial: 11447379
Drug: Prednisone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (30 mg twice daily for 3 days)
Trial: 8064166
Drug: Captopril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (1 mg/kg, oral)
Trial: 8064166
Drug: Remikiren (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren (1 mg/kg, intravenous infusion over 60 min)
Trial: 1932670
Drug: High-dose terlipressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose terlipressin
Trial: 1932670
Drug: Low-dose terlipressin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose terlipressin
Trial: 6119724
Drug: Melperone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone 10 mg
Trial: 6119724
Drug: Melperone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone 25 mg
Trial: 6119724
Drug: Melperone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone 50 mg
Trial: 6119724
Drug: Thioridazine 10
RxNorm normalized name: thioridazine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine 10 mg
Trial: 6119724
Drug: Thioridazine 25
RxNorm normalized name: thioridazine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine 25 mg
Trial: 6119724
Drug: Levomepromazine 10
RxNorm normalized name: Lévomépromazine
DrugBank: Methotrimeprazine (DB01403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomepromazine 10 mg
Trial: 6119724
Drug: Levomepromazine 25
RxNorm normalized name: Lévomépromazine
DrugBank: Methotrimeprazine (DB01403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomepromazine 25 mg
Trial: 6119724
Drug: Levomepromazine 50
RxNorm normalized name: Lévomépromazine
DrugBank: Methotrimeprazine (DB01403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomepromazine 50 mg
Trial: 6119724
Drug: Chlorprotixene 10
RxNorm normalized name: Chlorprotixene
DrugBank: Chlorprothixene (DB01239)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorprotixene 10 mg
Trial: 6119724
Drug: Chlorprotixene 25
RxNorm normalized name: Chlorprotixene
DrugBank: Chlorprothixene (DB01239)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorprotixene 25 mg
Trial: 6119724
Drug: Chlorprotixene 50
RxNorm normalized name: Chlorprotixene
DrugBank: Chlorprothixene (DB01239)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorprotixene 50 mg
Trial: 29193937
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tamsulosin and Oxybutynin
Trial: 25549690
Drug: Computer-based phoneme-discrimination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based phoneme-discrimination training (twice a week for three weeks)
Trial: 15157690
Drug: 10 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg.kg(‐1) body weight caffeine
Trial: 15157690
Drug: 5 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg.kg(‐1) body weight caffeine
Trial: 11307042
Drug: Ro 41-3696
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 41-3696 at 10 mg
Trial: 11307042
Drug: Ro 41-3696
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 41-3696 at 3 mg
Trial: 11307042
Drug: Ro 41-3696
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 41-3696 at 5 mg
Trial: 11307042
Drug: Ro 41-3696
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 41-3696 at 1 mg
Trial: 7805371
Drug: Gestodene 75
RxNorm normalized name: ethinyl estradiol 30 MCG / gestodene 75 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestodene 75 mcg plus ethinyl estradiol 30 mcg
Trial: 7805371
Drug: Desogestrel 150
RxNorm normalized name: Desogestrel 150 microgram and ethinylestradiol 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel 150 mcg plus ethinyl estradiol 30 mcg
Trial: 3280000
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin A (CyA) at a mean dose of 5.5 mg/kg/day
Trial: 3280000
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin A (CyA) at a mean dose of 5.6 mg/kg/day
Trial: 3280000
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin A (CyA) at a lower mean dose of 3 mg/kg/day during tapering off phase
Trial: 3280000
Drug: CyA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA treatment
Trial: 28555959
Drug: Spironolactone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (12.5 mg with eventual escalation to 25 mg daily over a 4-week period)
Trial: 24455542
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A (66 Gy in 33 fractions, 5 fractions/week, with concomitant chemotherapy - Cisplatin 30 mg/m² IV once weekly for 6 weeks)
Trial: 24455542
Drug: Arm C
RxNorm normalized name: Forearm Crutch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm C (30 Gy in 15 fractions followed by 1.4 Gy twice daily for 15 days, total 72 Gy in 6 weeks)
Trial: 21526444
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose transdermal nicotine (21/14 mg for men/women)
Trial: 21526444
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose transdermal nicotine (7 mg)
Trial: 12652326
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (0.25 mg/kg bolus plus a maintenance infusion)
Trial: 12652326
Drug: Intravenous digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous digoxin (13 mcg/kg)
Trial: 10751074
Drug: Once-weekly rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-weekly rifapentine + isoniazid (HRp1)
Trial: 10751074
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times weekly isoniazid + rifampicin (HR3)
Trial: 8609830
Drug: Adjuvant recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant recombinant human growth hormone (rhGH) treatment (0.15 mg/kg/d)
Trial: 1575820
Drug: bezafibrate 600
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate 600 mg/day
Trial: 30232699
Drug: Bisoprolol-Amlodipine 5
RxNorm normalized name: perindopril, bisoprolol, amlodipine and indapamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablet
Trial: 30232699
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet (Control)
Trial: 27634471
Drug: Robot Gym
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot Gym therapy (technology-assisted rehabilitation)
Trial: 22308241
Drug: COGRAT (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COGRAT (Cognitive therapy + Graded activity training)
Trial: 22308241
Drug: CO (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO (Cognitive therapy only)
Trial: 20736151
Drug: Maraviroc +
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc + Optimized Background Therapy (OBT)
Trial: 20736151
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Optimized Background Therapy (OBT)
Trial: 17585116
Drug: Erythromycin 2
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 2 days + midazolam (2.5 mg) (EM2)
Trial: 17585116
Drug: Erythromycin 4
RxNorm normalized name: erythromycin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 4 days + midazolam (2.5 mg) (EM4)
Trial: 17585116
Drug: Erythromycin 7
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin 7 days + midazolam (2.5 mg) (EM7)
Trial: 17585116
Drug: Midazolam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (5 mg) without erythromycin (EM0)
Trial: 12227708
Drug: Bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (400 mg/day) for 6 months
Trial: 10509849
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg once daily for nonulcer patients, 20 mg twice daily for ulcer patients for 14 days) plus two antimicrobials (amoxicillin, clarithromycin or roxithromycin, metronidazole, ornidazole, or tinidazole for 10 days)
Trial: 7760866
Drug: Six weeks
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six weeks of oral anticoagulant therapy (warfarin or dicumarol)
Trial: 7760866
Drug: Six months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six months of oral anticoagulant therapy (warfarin or dicumarol)
Trial: 2179082
Drug: D,L-Kavain (Neuronika)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D,L-Kavain (Neuronika)
Trial: 27933512
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine treatment (Zuogui Pill and Yougui Pill for low risk; Qingwen Baidu Decoction and Bazhen Decoction for moderate risk; Gexia Zhuyu Decoction and Qinghao Biejia Decoction combined with Shiquan Dabu Decoction for high risk)
Trial: 21067823
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine hydrochloride (20 mg/ml) with 0.00125% epinephrine
Trial: 21067823
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% bupivacaine hydrochloride
Trial: 15459217
Drug: R115777 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R115777 (300 mg twice daily)
Trial: 9540015
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diet plus exercise
Trial: 9540015
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (diet, exercise, combination)
Trial: 8210250
Drug: MST-16 at
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST-16 at 1,600 mg/body for 5 consecutive days repeating every 4 weeks
Trial: 8210250
Drug: MST-16 at
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST-16 at 1,200 mg/body for 10-14 consecutive days every 5 weeks
Trial: 8210250
Drug: MST-16 at
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST-16 at 1,200 mg/body daily for at least 4 weeks
Trial: 8210250
Drug: MST-16 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST-16 (all doses)
Trial: 22216522
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg and 200 mg daily)
Trial: 22216522
Drug: Practolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (200 mg and 400 mg daily)
Trial: 30413829
Drug: Non-pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological therapy
Trial: 25398967
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus Vitamin D3 (1000 mg/d of calcium plus 400 IU/d of vitamin D3)
Trial: 23514701
Drug: TMP transdermal
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TMP transdermal patch
Trial: 23514701
Drug: TMP oral
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TMP oral tablets (TMPP)